C4 Therapeutics (CCCC) Non-Current Assets (2019 - 2026)

C4 Therapeutics' Non-Current Assets history runs 8 years deep, the most recent figure standing at $83.5 million for Q1 2026.

• In Q1 2026, Non-Current Assets fell 4.02% year-over-year to $83.5 million; the TTM figure through Mar 2026 stood at $314.9 million (down 18.57% YoY), while the FY2025 annual figure was $101.0 million, up 9.94% from the prior year.
• Non-Current Assets was $83.5 million for Q1 2026 at C4 Therapeutics, down from $101.0 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $212.5 million in Q1 2022 to a low of $58.6 million in Q3 2025.
• Historically, Non-Current Assets has averaged $112.9 million across 5 years, with a median of $105.0 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Non-Current Assets soared 308.76% in 2022, then tumbled 44.68% in 2023.
• A 5-year view of Non-Current Assets shows it stood at $143.3 million in 2022, then fell by 26.54% to $105.3 million in 2023, then fell by 12.76% to $91.8 million in 2024, then grew by 9.94% to $101.0 million in 2025, then decreased by 17.31% to $83.5 million in 2026.
• The last three Non-Current Assets figures came in at $83.5 million (Q1 2026), $101.0 million (Q4 2025), and $58.6 million (Q3 2025), per Business Quant data.